10.17.25 -- Comparing Manual Vs. Automated Processing And Thawing Systems

The 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4, Philadelphia, PA) is your insider access pass to the latest cutting-edge data driving clinical progression across the autoimmune cell therapy. Immerse yourself in the future of autoimmune treatment with a revitalized agenda and an 80% new speaker panel, showcasing innovations translating clinical promise into meaningful patient outcomes. Find out more

In this segment of our Cell & Gene Live, Optimizing Storage Solutions for iPSCs, expert panelists Pratik Jaluria, Ph.D., SVP Technical Development Strategy at BlueRock Therapeutics, Bruno Marques, Ph.D. VP, Process and Product Development at Century Therapeutics, and Kate Rochlin, Ph.D., COO at IN8bio share that a well-constructed manual operation can be matched by an automated system, but there is a higher capital expenditure.

In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, emphasized that natural killer (NK) cells require distinct, tailored activation methods to unlock their full therapeutic potential in cancer. They argued that unfair comparisons with T cells hinder innovation and highlighted how NK-focused engineering boosts both persistence and cytotoxicity.

This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines.

Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now